Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentuximab and Almonertinib in EGFR-mutated Metastatic NSCLC
NCT05223595Phase 1Unknown
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gentuximab, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicities up to 4 Weeks and Adverse Events up to 2 years. Status: unknown.
02
Drugs
gentuximab
Beyond the preview
Go deeper on NCT05223595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223595.